BACKGROUND AND PURPOSE: : Since the efficacy of a single targeted agent in combination with ionizing radiation is limited by putative treatment resistances, a rationally designed triple treatment consisting of an agonistic antibody targeting either TRAIL-R1 (mapatumumab) or TRAIL-R2 (lexatumumab), radiation and an epidermal growth factor receptor-(EGFR-)inhibiting antibody (cetuximab) was tested. MATERIAL AND METHODS: : Induction of apoptosis after triple treatment was determined in Colo205, HCT116 and FaDu cells by Hoechst 33342 stain. The degree of interaction was determined by isobologram analysis. A knockout variant of HCT116 was used to examine Bax dependence of the triple treatment. The role of Akt/PKB signaling was analyzed using the phosphatidylinositol 3-kinase inhibitor LY294002. Clonogenic assays were performed to examine the effect on clonogenic survival of tumor cells. RESULTS: : A synergistic effect of radiation, cetuximab and agonistic TRAIL-R antibodies was demonstrated in cell lines derived from colorectal tumors or head-and-neck cancers. The efficacy of this multimodal approach was dependent on Bax and inhibition of Akt/PKB in the cell systems used. The results also show a positive impact on clonogenic cell death in several cell lines. CONCLUSION: : These data suggest that rationally designed multimodal therapy approaches integrating radiation with more than one targeted agent will open new perspectives in radiation oncology.
BACKGROUND AND PURPOSE: : Since the efficacy of a single targeted agent in combination with ionizing radiation is limited by putative treatment resistances, a rationally designed triple treatment consisting of an agonistic antibody targeting either TRAIL-R1 (mapatumumab) or TRAIL-R2 (lexatumumab), radiation and an epidermal growth factor receptor-(EGFR-)inhibiting antibody (cetuximab) was tested. MATERIAL AND METHODS: : Induction of apoptosis after triple treatment was determined in Colo205, HCT116 and FaDu cells by Hoechst 33342 stain. The degree of interaction was determined by isobologram analysis. A knockout variant of HCT116 was used to examine Bax dependence of the triple treatment. The role of Akt/PKB signaling was analyzed using the phosphatidylinositol 3-kinase inhibitor LY294002. Clonogenic assays were performed to examine the effect on clonogenic survival of tumor cells. RESULTS: : A synergistic effect of radiation, cetuximab and agonistic TRAIL-R antibodies was demonstrated in cell lines derived from colorectal tumors or head-and-neck cancers. The efficacy of this multimodal approach was dependent on Bax and inhibition of Akt/PKB in the cell systems used. The results also show a positive impact on clonogenic cell death in several cell lines. CONCLUSION: : These data suggest that rationally designed multimodal therapy approaches integrating radiation with more than one targeted agent will open new perspectives in radiation oncology.
Authors: Klaus Dittmann; Claus Mayer; Birgit Fehrenbacher; Martin Schaller; Uma Raju; Luka Milas; David J Chen; Rainer Kehlbach; H Peter Rodemann Journal: J Biol Chem Date: 2005-07-05 Impact factor: 5.157
Authors: Christian Weiss; Franz Rödel; Oliver Ott; Dirk Gerhard Engehausen; Thomas Papadopoulos; Rolf Sauer; Claus Rödel Journal: Strahlenther Onkol Date: 2007-10 Impact factor: 3.621
Authors: Frank Michael Klenke; Amir Abdollahi; Marc Bischof; Martha-Maria Gebhard; Volker Ewerbeck; Peter E Huber; Axel Sckell Journal: Strahlenther Onkol Date: 2010-12-23 Impact factor: 3.621
Authors: Frederick Mantel; Benjamin Frey; Stefan Haslinger; Petra Schildkopf; Renate Sieber; Oliver J Ott; Barbara Lödermann; Franz Rödel; Rolf Sauer; Rainer Fietkau; Udo S Gaipl Journal: Strahlenther Onkol Date: 2010-11-08 Impact factor: 3.621
Authors: T Trarbach; M Moehler; V Heinemann; C-H Köhne; M Przyborek; C Schulz; V Sneller; G Gallant; S Kanzler Journal: Br J Cancer Date: 2010-01-12 Impact factor: 7.640
Authors: Michael Orth; Kirsten Lauber; Maximilian Niyazi; Anna A Friedl; Minglun Li; Cornelius Maihöfer; Lars Schüttrumpf; Anne Ernst; Olivier M Niemöller; Claus Belka Journal: Radiat Environ Biophys Date: 2013-10-20 Impact factor: 1.925